* Sensei Biotherapeutics Inc is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Sensei Biotherapeutics Inc is for a loss of 31 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Sensei Biotherapeutics Inc is 4.00, above its last closing price of $0.47.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.30 -0.29 -0.28 Beat 2.9
Mar. 31 2024 -0.27 -0.27 -0.32 Missed -16.4
Dec. 31 2023 -0.31 -0.31 -0.30 Beat 2.5
Sep. 30 2023 -0.34 -0.34 -0.28 Beat 17.4
Jun. -0.33 -0.33 -0.31 Beat 6.2
30 2023
Mar. 31 2023 -0.36 -0.36 -0.33 Beat 7.3
Dec. 31 2022 -0.39 -0.40 -0.40 Met 0
Sep. 30 2022 -0.37 -0.37 -0.44 Missed -18.9
This summary was machine generated November 1 at 14:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。